Eagle Pharmaceuticals Inc (EGRX) Fair Value & Analysis

Healthcare · US · Market cap $3.3M · ISIN US2697961082

A solid business, but trading 330% above our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($0.3333). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range ($0.1612 to $0.3333) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.0010 – $56.90 · fair‑value band $0.1612 – $0.3333 · the $0.9250 price screens above the $0.2149 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Eagle Pharmaceuticals Inc (EGRX) currently trades at $0.9250, while our model-based Fair Value estimate is $0.2149, implying the stock looks roughly 76.8% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Eagle Pharmaceuticals Inc generated revenue of $258M at a net margin of 4.6%. Revenue declined 12.8% year over year. It earns a return on equity of 4.9%. Net debt stands at $12.5M. Fundamentals as of Aug 13, 2026

Our scenario range runs from $0.1612 (bear case) to $0.3333 (bull case); at $0.9250, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 76% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside, at -77%, EGRX screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings ($0.3273) versus Dividend Discount ($0.0053). Highest evidence: FCF DCF (78).

Key figures & financial health

Quality Score breakdown

About the company

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

Full company description

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2018 – FY2022 · reported fiscal years

Eagle Pharmaceuticals Inc reported revenue of $317M in FY2022 versus $213M in FY2018, a compound +10.4%/yr. Reported net income was $35.6M in FY2022, compounding +2.8%/yr from FY2018.

EGRX screens 330% overvalued. Compare with Merck KGaA →

Peer Group

Drug Manufacturers - Specialty & Generic · 637 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.